Frog Gut Bacteria Shows Promise in Completely Eradicating Tumors in Mice
Table of Contents
A groundbreaking new study reveals that gut bacteria from a Japanese tree frog could hold the key to fighting cancer, with one strain, Ewingella americana, completely eliminating tumors in mice without causing significant side effects.
Researchers at the Japan Advanced Institute of Science and Technology embarked on this innovative research path after observing that amphibians and reptiles rarely develop cancer. The team hypothesized that transferring gut bacteria from these creatures to mice could potentially unlock anti-cancer effects.
The Search for Anti-Cancer Microbes
The investigation began with a shortlist of 45 different bacterial strains sourced from frogs, newts, and lizards. Initial testing identified nine strains exhibiting notable tumor-fighting capabilities. However, Ewingella americana, isolated from the Japanese tree frog (Dryophytes japonicus), emerged as the most promising candidate.
“These findings suggest that gut microbiomes of lower vertebrates harbor numerous uncharacterized bacterial species with exceptional therapeutic potential,” the researchers wrote in their published paper, appearing in Gut Microbes in 2025.
Complete Tumor Regression Observed in Mice
Unlike other strains that demonstrated only temporary anti-tumor effects, a single dose of E. americana resulted in the complete disappearance of tumors in treated mice. Remarkably, when cancer cells were reintroduced 30 days later, tumors failed to develop over the subsequent month.
The bacteria’s mechanism of action appears to be twofold. E. americana directly attacks tumor tissue while simultaneously boosting the body’s immune response, activating crucial immune cells like T cells, B cells, and neutrophils.
Exploiting the Tumor Microenvironment
Researchers believe E. americana‘s effectiveness stems from its ability to thrive in the low-oxygen environments characteristic of cancer tumors. These conditions typically suppress immune cell activity and diminish the efficacy of traditional chemotherapy drugs. By surviving and functioning in these challenging environments, E. americana can overcome these limitations.
Preliminary animal studies indicate a strong safety profile for E. americana. The bacteria were rapidly cleared from the mice’s bloodstream, exhibited no long-term toxicity, and did not appear to harm healthy organs. In fact, injections of E. americana proved more effective at shrinking tumors than doxorubicin, a commonly used chemotherapy drug.
“These results suggest that E. americana represents a promising therapeutic candidate with an acceptable safety profile suitable for potential clinical development,” the researchers stated.
Future Research and Clinical Trials
While these findings are highly encouraging, researchers emphasize that this is still early-stage research. Extensive testing is needed to determine if the results observed in mice can be replicated in humans. Future studies will focus on evaluating E. americana against various cancer types, exploring its synergistic effects with existing treatments, and optimizing drug delivery methods.
Safety remains a paramount concern as the research progresses toward potential clinical trials. As a bacterium, E. americana carries the inherent risk of causing infections, and ensuring its safe use in humans will be a significant challenge.
However, the potential benefits are substantial. Scientists are already exploring other avenues of harnessing bacteria to combat cancer, with at least one bacterial therapy currently approved for treating certain cases of bladder cancer. Frogs and other reptiles may offer a valuable, untapped resource for discovering additional cancer therapeutics.
“Our findings demonstrate the vast untapped potential residing within diverse microbial ecosystems and highlight the critical importance of biodiversity conservation efforts in advancing medical science and therapeutic innovation,” the researchers concluded.
The research has been published in Gut Microbes.
